Top Medical News from Across Medscape

  • Antibiotics, Antidepressants Predominate New FDA Watch ListPresence on list does not mean a drug has been linked to a risk, only that new safety information is available or potential risk has been identified and further review will be or has been completed.
  • MGUS in 3% of Population: What to Do?Evidence for clinical practice and follow-up is limited, and experts offer suggestions based on the literature and their own practice at the Mayo Clinic.
  • More Evidence Links Gum Disease to Stroke RiskA new study shows a relationship between severity of gum disease and increasing future stroke risk, and conversely that regular dental care was linked to a lower stroke risk.
  • Experts Welcome Adjuvant Nivolumab for MelanomaThe PD-1 inhibitor nivolumab was recently approved by the FDA for adjuvant use in completely resected stage III or IV melanoma, a move welcomed by experts in the field.

Special Report

Business of Medicine

Medscape Editor-in-Chief

  • Eric J. Topol, MD Director, Scripps Translational Science Institute; Chief Academic Officer, Scripps Health; Professor of Genomics, The Scripps Research Institute, La Jolla, California